Hospital
Sacred Heart Hospital of the Hospital Sisters-3Rd Order of ST Francis
Sacred Heart Hospital of the Hospital Sisters-3Rd Order of ST Francis was paid $5.63M by Medicaid between Jan 2018 and Mar 2024, across 186 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoSACRED HEART HOSPITAL OF THE HOSPITAL SISTERS-3RD ORDER OF ST FRANCIS
EAU CLAIRE, WI 54701
EAU CLAIRE, WI 54701
33aNPI1205811221assigned 12/13/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.63M
24GClaims334,461
24DCodes billed186
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#23 of 60
Median peer was paid$2.90M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ALLEN, PATRICIA controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,535 | $995K | |
| 2019 | 42,490 | $830K | |
| 2020 | 43,300 | $712K | |
| 2021 | 58,606 | $843K | |
| 2022 | 62,334 | $986K | |
| 2023 | 66,439 | $1.10M | |
| 2024incomplete | 8,757 | $171K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 9,853 | 8,616 | $581K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 9,448 | 8,098 | $414K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.2% | 4,651 | 3,046 | $408K |
| 80053 | Comprehensive metabolic panel | 6.7% | 16,008 | 12,123 | $377K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.4% | 3,369 | 3,022 | $249K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.3% | 3,641 | 3,242 | $242K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.6% | 3,302 | 2,904 | $203K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 3,824 | 2,006 | $196K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 5,109 | 4,408 | $186K |
| 80306 | 2.7% | 3,158 | 2,613 | $154K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 3,379 | 2,970 | $152K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.4% | 3,137 | 2,571 | $138K |
174 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 2,963 | $124K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 21,267 | $123K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 5,064 | $103K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 1,760 | $98K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 2,903 | $92K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 1,847 | $92K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 2,902 | $88K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.5% | 742 | $87K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 1,404 | $77K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 852 | $70K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,209 | $66K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 1,194 | $63K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 1,975 | $58K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,930 | $56K |
| 82948 | <1% | 6,556 | $46K | |
| 84484 | <1% | 5,799 | $46K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 764 | $45K |
| G0378 | Hospital observation service, per hour | <1% | 2,265 | $43K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,404 | $41K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 706 | $41K |
| 87507 | <1% | 122 | $39K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 846 | $38K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,330 | $38K |
| 81025 | <1% | 3,675 | $35K | |
| 88142 | <1% | 1,984 | $35K | |
| 87430 | <1% | 922 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,601 | $30K |
| 87077 | <1% | 2,545 | $27K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 328 | $26K |
| 81001 | <1% | 6,951 | $26K | |
| 96367 | <1% | 461 | $24K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,029 | $23K |
| 86140 | <1% | 5,077 | $22K | |
| 87653 | <1% | 640 | $20K | |
| 83735 | <1% | 5,025 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 352 | $19K |
| 83880 | <1% | 1,361 | $18K | |
| 83690 | <1% | 3,618 | $18K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 238 | $17K |
| 83605 | <1% | 2,299 | $16K | |
| 81003 | <1% | 3,660 | $16K | |
| 87040 | <1% | 2,610 | $15K | |
| 87205 | <1% | 2,247 | $15K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 419 | $13K |
| 87088 | <1% | 2,004 | $13K | |
| 87186 | <1% | 2,094 | $13K | |
| 84702 | <1% | 544 | $13K | |
| 86803 | <1% | 1,107 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 262 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,851 | $12K |
| 87070 | <1% | 1,139 | $11K | |
| 74018 | <1% | 991 | $11K | |
| 85610 | <1% | 4,419 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 787 | $10K |
| 85379 | <1% | 1,417 | $9K | |
| 87081 | <1% | 1,446 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 145 | $8K |
| 84439 | <1% | 872 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 108 | $6K |
| 82565 | <1% | 567 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,340 | $6K |
| 85730 | <1% | 2,292 | $6K | |
| 80050 | General health panel | <1% | 1,371 | $5K |
| 84145 | <1% | 410 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 74 | $5K |
| 82607 | <1% | 402 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 29 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 653 | $4K |
| 87808 | <1% | 365 | $4K | |
| 87340 | <1% | 550 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,015 | $4K |
| 82550 | <1% | 736 | $4K | |
| 83550 | <1% | 586 | $4K | |
| 85027 | <1% | 531 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,451 | $3K |
| 83540 | <1% | 688 | $3K | |
| 86618 | <1% | 240 | $3K | |
| 86850 | <1% | 593 | $3K | |
| 87807 | <1% | 133 | $3K | |
| 93458 | <1% | 15 | $3K | |
| 93971 | <1% | 149 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 83 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 171 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,173 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 59 | $2K |
| 84703 | <1% | 295 | $2K | |
| 86780 | <1% | 249 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,495 | $2K |
| 82247 | <1% | 18 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 322 | $2K |
| 73610 | <1% | 186 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 34 | $1K |
| 86900 | <1% | 833 | $1K | |
| 86901 | <1% | 834 | $1K | |
| 73564 | <1% | 136 | $1K | |
| 82803 | <1% | 53 | $942.60 | |
| 82728 | <1% | 71 | $895.18 | |
| 82570 | <1% | 164 | $842.73 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 34 | $831.42 |
| 59025 | Fetal non-stress test | <1% | 15 | $811.62 |
| 97161 | <1% | 25 | $695.83 | |
| 85018 | <1% | 357 | $650.24 | |
| 83970 | <1% | 30 | $639.31 | |
| 73630 | <1% | 231 | $631.96 | |
| 84100 | <1% | 226 | $625.66 | |
| 76830 | Ultrasound, transvaginal | <1% | 22 | $580.65 |
| 85652 | <1% | 371 | $571.47 | |
| 97162 | <1% | 49 | $552.05 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,295 | $475.28 |
| 87207 | <1% | 65 | $299.64 | |
| Q3014 | Telehealth originating site facility fee | <1% | 29 | $283.67 |
| 80076 | <1% | 75 | $275.95 | |
| 88342 | <1% | 71 | $264.11 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14 | $259.08 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 33 | $257.64 |
| 80061 | Lipid panel | <1% | 49 | $242.73 |
| J3490 | Unclassified drugs | <1% | 7,064 | $229.02 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,073 | $202.79 |
| 97166 | <1% | 20 | $196.90 | |
| 84481 | <1% | 13 | $180.80 | |
| 36592 | <1% | 84 | $177.00 | |
| 88304 | <1% | 97 | $169.32 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 409 | $158.07 |
| 84156 | <1% | 45 | $111.37 | |
| 86308 | <1% | 17 | $95.10 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,476 | $84.31 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,060 | $72.33 |
| 90715 | <1% | 14 | $68.85 | |
| 84460 | <1% | 15 | $44.31 | |
| A9270 | Non-covered item or service | <1% | 6,610 | $43.82 |
| 96376 | <1% | 1,417 | $42.41 | |
| 84132 | <1% | 19 | $39.76 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,144 | $38.54 |
| 82553 | <1% | 15 | $35.50 | |
| 72100 | <1% | 29 | $19.24 | |
| 73130 | <1% | 34 | $18.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,453 | $7.21 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,035 | $5.11 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,104 | $4.61 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,947 | $4.46 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 821 | $2.17 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,064 | $0.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,022 | $0.30 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 28 | $0.28 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,943 | $0.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 695 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 180 | $0.00 |
| 73110 | 0% | 13 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 403 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 344 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 236 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 206 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 36 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 2,680 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,077 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 263 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 347 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 978 | $0.00 |
| 94760 | 0% | 440 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,262 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 224 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 64 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 134 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 50 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 49 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 123 | $0.00 |
| C1769 | Guide wire | 0% | 46 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 101 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 61 | $0.00 |
| 74019 | 0% | 54 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALLEN, PATRICIA (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.